Business Wire

Einride Enables the Switch to Sustainable Freight in the UK

Share

Einride, a freight mobility company that provides digital, electric and autonomous technology, today announces the expansion of its operations into the United Kingdom. This marks a pivotal moment for the UK, where around 1.4 billion tonnes of goods are transported around the country by road each year, and where road haulage is responsible for over 20% of domestic carbon emissions. The UK Department for Transport is currently looking to build a sustainable future of freight, where goods are moved through cost-efficient, reliable, resilient, seamless and net zero means – a vision that Einride shares.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418006107/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Einride launches in the UK (Photo: Business Wire)

Putting the UK on the fast track towards net zero goal

Through an ecosystem of products including the intelligent platform Einride Saga, electric and autonomous fleets, charging infrastructure and connectivity networks, Einride will provide the UK with a new and sustainable end-to-end road freight solution. With these technologies, Einride will establish a regional freight mobility grid along the M1, M5 and M6 between the major metropolitan cities of London, Sheffield, Manchester, Birmingham and Bristol. The starting point will be the Midlands’ ‘golden logistics triangle,’ which lies within four hours’ drive of 90% of the British population and contains a significant share of the country’s logistics and warehousing facilities.

“The UK has always been at the forefront of transport history. The efficient and innovative movement of goods has consistently been integral to the growth and prosperity of the UK, with the British pioneering both the railway system and canal networks,” said Robert Falck, Founder and CEO of Einride. “We’re honoured to be here, teaming up with local partners to further establish the UK as a transport pioneer and ultimately help the country meet its net zero goals.”

First commercial partnership with PepsiCo’s Walkers brand

Einride’s first commercial partner in the UK, PepsiCo, will have an initial deployment using Einride connected electric trucks between its Walkers manufacturing sites in Leicester and Coventry. Over the three-year partnership, the truck fleet, powered by Einride’s intelligent Saga platform, will cover more than 750,000 miles previously powered by fossil-fuels, reducing the equivalent of over 1,600 tonnes of CO2 emissions.

“At PepsiCo, we are committed to reducing the environmental impact of our business, with a goal of reaching net zero emissions by 2040 as part of our PepsiCo Positive agenda,” said Archana Jagannathan, Head of Sustainability, PepsiCo UK. “Our partnership with Einride is a small yet important step towards that ambition, one that will help us drive meaningful progress in sustainable transport. With this initial deployment, we’re looking forward to better understanding the potential role electric trucks can play in our transport operations.”

Grids accelerate access to electrification

As in other markets, Einride’s UK freight ecosystem will operate on a grid that is planned, optimised and monitored through the Einride Saga platform. The grid concept simplifies freight management over long distances and removes inefficiencies that are otherwise typical for the industry, with smart handovers meaning goods don’t have to be delayed due to battery recharges or a change in driver. Einride takes overall responsibility for all logistical touchpoints, from intelligent software to reliable charging infrastructure and maintenance services, to provide a holistic and high quality service.

Einride plans to establish a vast network of partners as it expands further into the UK and Ireland, connecting additional shippers and operators which will enable cost-efficient scaling of the grid together with increased emission savings. Once a critical mass of transportation volumes is established, the expansion of the grid will be further supported by algorithmic optimisation provided by Einride Saga and by introducing human-led autonomous technologies such as Einride’s heavy duty, cabless trucks which are monitored by a remote operator.

Today’s launch follows Einride’s 2022 expansion into Germany, Belgium, Luxembourg, the Netherlands and Norway. The company is the leading operator of heavy-duty electric freight in Sweden and the US, and across its markets, Einride operates fleets for industry giants such as Maersk, AB InBev, Lidl and GE Appliances, a Haier company. Since electrifying their road freight with Einride, partners have seen an up to 95% decrease in CO2 emissions while remaining cost competitive.

About Einride

Einride designs, develops and deploys technologies for freight mobility. By building grids powered by a first-of-its-kind ecosystem — the intelligent platform Einride Saga, electric and autonomous fleets, charging infrastructure and connectivity networks — a resilient, cost-effective shipping future is unlocked. Founded in 2016, Einride became the first company in the world to deploy an autonomous, electric vehicle on a public road in 2019 and became the first company to receive approval to operate the vehicle on a US public road in 2022. For more information, please visit einride.tech.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maja Ruhbach, press@einride.tech

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye